Our analysis also confirms that patients with higher BCL-2 expression had inferior OS, paralleling emerging data that anti-apoptotic regulators such as BCL-2, BCL-XL, and MCL-1 can act as “pro-survival” crutches for MDS cells [23,27]. This evidence concerns the gene BCL2L1 and myelodysplastic syndrome.